Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation

Journal of the American Academy of Dermatology

Volumn 61, Issue 6, 2009, Pages 1044-1055

  Frankel, Amylynne J ^a   Van Voorhees, Abby S ^b   Hsu, Sylvia ^c   Korman, Neil J ^d   Lebwohl, Mark G ^e   Bebo Jr , Bruce F ^f   Gottlieb, Alice B ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f National Psoriasis Foundation   (United States)

Author keywords

hepatitis C; phototherapy; psoriasis; systemic therapy; topical therapy

Indexed keywords

ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; CALCIPOTRIOL; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PLACEBO; PSORALEN; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; LIVER TOXICITY; MEDICAL LITERATURE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

HEPATITIS C, CHRONIC; HUMANS; LIVER; PSORIASIS;

EID: 71649088247     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.03.044     Document Type: Review

References (68)

1. Magliocco M.A., and Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004) 580-584
2. Calabrese L.H., Zein N., and Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63 Suppl (2004) ii18-24
3. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005) 315-322
4. Citro V., Fristachi R., and Tarantino G. Extensive psoriasis induced by pegylated interferon: a case report. J Med Case Rep 1 (2007) 86
5. Taylor C., Burns D.A., and Wiselka M.J. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J 76 (2000) 365-367
6. Methotrexate [package insert] (2005), Bedford Laboratories, Bedford, OH
7. Neoral (cyclosporine) [package insert] (2002), Novartis Pharmaceuticals Corp, East Hanover, NJ
8. Soriatane [package insert] (1997), Roche Laboratories, Nutley, NJ
9. Enbrel (etanercept) [package insert] (2004), Immunex Corp, Thousand Oaks, CA
10. Pariser D.M., and Wyles R.J. Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA). J Am Acad Dermatol 3 (1980) 248-250
11. Clements P.J., and Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum 15 (1986) 231-254
12. Markin R.S., Donovan J.P., Shaw Jr. B.W., and Zetterman R.K. Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis. J Clin Gastroenterol 17 (1993) 311-313
13. Ashton R.E., Millward-Sadler G.H., and White J.E. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 79 (1982) 229-232
14. Orion E., Matz H., and Wolf R. The life-threatening complications of dermatologic therapies. Clin Dermatol 23 (2005) 182-192
15. Shekelle P.G., Woolf S.H., Eccles M., and Grimshaw J. Clinical guidelines: developing guidelines. BMJ 318 (1999) 593-596
16. Thaci D., Patzold S., Kaufmann R., and Boehncke W.H. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol 152 (2005) 1048-1050
17. Bellisai F., Giannitti C., Donvito A., and Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 26 (2007) 1127-1129
18. Imafuku S., Tashiro A., and Furue M. Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C. Br J Dermatol 156 (2007) 1367-1369
19. Feldman S.R., Gelfand J.M., Stein Gold L., and Jones S.D. The role of topical therapy for patients with extensive psoriasis. Cutis 79 (2007) 18-31
20. Gorgievska Sukarovska B., and Lipozencic J. Topical management of psoriasis-corticosteroids and sparing corticosteroid therapy. Acta Dermatovenerol Croat 14 (2006) 188-196
21. Dawe R.S., Cameron H., Yule S., Man I., Ibbotson S.H., and Ferguson J. UV-B phototherapy clears psoriasis through local effects. Arch Dermatol 138 (2002) 1071-1076
22. Simon J.C., Pfieger D., and Schopf E. Recent advances in phototherapy. Eur J Dermatol 10 (2000) 642-645
23. Jones C.D., Guckian M., el-Ghorr A.A., Gibbs N.K., and Norval M. Effects of phototherapy on the production of cytokines by peripheral blood mononuclear cells and on systemic antibody responses in patients with psoriasis. Photodermatol Photoimmunol Photomed 12 (1996) 204-210
24. Nyfors A., Dahl-Nyfors B., and Hopwood D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients; a blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol 14 (1986) 43-48
25. Zachariae H., Kragballe K., and Sogaard H. Liver biopsy in PUVA-treated patients. Acta Derm Venereol 59 (1979) 268-270
26. Bjellerup M., Bruze M., Hansson A., Krook G., and Ljunggren B. Liver injury following administration of 8-methoxypsoralen during PUVA therapy. Acta Derm Venereol 59 (1979) 371-372
27. Bjellerup M., Bruze M., Krook G., and Ljunggren B. Toxic hepatitis after PUVA. J Am Acad Dermatol 4 (1981) 481
28. Weiss V.C., Layden T., Spinowitz A., Buys C.M., Nemchausky B.A., West D.P., et al. Chronic active hepatitis associated with etretinate therapy. Br J Dermatol 112 (1985) 591-597
29. Vahlquist A., Loof L., Nordlinder H., Rollman O., and Vahlquist C. Differential hepatotoxicity of two oral retinoids (etretinate and isotretinoin) in a patient with palmoplantar psoriasis. Acta Derm Venereol 65 (1985) 359-362
30. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol 27 Suppl (1992) S29-S33
31. Katz H.I., Waalen J., and Leach E.E. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 41 Suppl (1999) S7-12
32. Roenigk Jr. H.H., Callen J.P., Guzzo C.A., Katz H.I., Lowe N., Madison K., et al. Effects of acitretin on the liver. J Am Acad Dermatol 41 (1999) 584-588
33. Cecchi R., and Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 12 (2006) 4
34. Rokhsar C., Rabhan N., and Cohen S.R. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 54 (2006) 361-362
35. De Simone C., Paradisi A., Capizzi R., Carbone A., Siciliano M., and Amerio P.L. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 54 (2006) 1102-1104
36. Marotte H., Fontanges E., Bailly F., Zoulim F., Trepo C., and Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 46 (2007) 97-99
37. Niewold T.B., and Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 54 (2006) 2335-2337
38. Linardaki G., Katsarou O., Ioannidou P., Karafoulidou A., and Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 34 (2007) 1353-1355
39. Peterson J.R., Hsu F.C., Simkin P.A., and Wener M.H. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viremia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082
40. Roux C.H., Brocq O., Breuil V., Albert C., and Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 45 (2006) 1294-1297
41. Oniankitan O., Duvoux C., Challine D., Mallat A., Chevalier X., Pawlotsky J.M., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004) 107-109
42. Abdelmalek M.F., Liu C., and Valentine J.F. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol 102 (2007) 1333-1334
43. Aslanidis S., Vassiliadis T., Pyrpasopoulou A., Douloumpakas I., and Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26 (2007) 261-264
44. Khanna M., Shirodkar M.A., and Gottlieb A.B. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 14 (2003) 229-232
45. Helliwell P.S., and Taylor W.J. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs-comparison of drugs and adverse reactions. J Rheumatol 35 (2008) 472-476
46. Vigna-Perez M., Abud-Mendoza C., Portillo-Salazar H., Alvarado-Sanchez B., Cuevas-Orta E., Moreno-Valdes R., et al. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 141 (2005) 372-380
47. Everson G.T. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 8 (2002) S19-S27
48. Oton E., Barcena R., Castillo M., Barreales M., Blesa C., Moreno-Planas J.M., et al. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Transplant Proc 38 (2006) 2499-2501
49. Kamar N., Selves J., Sandres-Saune K., Durand D., Izopet J., and Rostaing L. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation?. Transplant Proc 38 (2006) 1329-1332
50. Raptiva [package insert]. South (2005), Genentech Inc, San Francisco, CA
51. Stangle J.R., Carroll K.L., Illichman M., and Striker R. Effect of antimetabolite immunosuppressants on flaviviridae, including hepatitis C virus. Transplantation 77 (2004) 562-567
52. Platz K.P., Mueller A.R., Berg T., Neuhaus R., Hopf U., Lobeck H., et al. Searching for the optimal management of hepatitis C patients after liver transplantation. Transplant Int 1 (1998) S209-S211
53. Henry S.D., Metselaar H.J., Lonsdale R.C., Kok A., Haagmans B.L., Tilanus H.W., et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 131 (2006) 1452-1462
54. Luan F.L., Schaubel D.E., Zhang H., Jia X., Pelletier S.J., Port F.K., et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 85 (2008) 1601-1606
55. Ashcroft D.M., Po A.L.W., Williams H.C., and Griffiths C.E.M. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 320 (2000) 963-967
56. Zonneveld I.M., Rubins A., Jablonska S., Dobozy A., Ruzicka T., Kind P., Dubertret L., and Bos J.D. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134 (1998) 1101-1102
57. Lebwohl M., Freeman A.K., Chapman M.S., Feldman S.R., Hatrle J.E., and Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51 (2004) 723-730
58. Gribetz C., Ling M., Lebwohl M., Pariser D., Draelos Z., Gottlieb A.B., et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51 (2004) 731-738
59. Cameron H., Dawe R.S., Yule S., Murphy J., Ibbotson S.H., and Ferguson J. A randomized, observer-blinded trial of twice vs three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 147 (2002) 973-978
60. Parrish J.A., Fitzpatrick T.B., Tanenbaum L., and Pathak M.A. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 291 (1974) 1207-1211
61. Wolff K.W., Fitzpatrick T.B., Parrish J.A., Gschnait F., Gilchrest B., Hönigsmann H., et al. Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol 112 (1976) 943-950
62. Weismann K., Howitz J., and Bro-Joergensen A. Treatment of resistant psoriasis with oral 8-methoxypsoralen and long-wave ultraviolet light (PUVA): A treatment schedule and a follow-up study. Acta Derm Venereol (Stockh) 57 (1977) 73-76
63. Melski J.W., Tannenbaum L., Parrish J.A., Fitzpatrick T.B., and Bleich H.L. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 68 (1977) 328-335
64. Martin P., Busuttil R.W., Goldstein R.M., Crippin J.S., Klintmalm G.B., Fitzsimmons W.E., and Uleman C. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 10 (2004) 1258-1262
65. Durak I., Ozbek H., and Serenay E. Cyclosporine reduces hepatic antioxidant capacity: protective roles of antioxidants. Int Immunopharmacol 4 (2004) 469-473
66. Henry S.D., Metselaar H.J., Lonsdale R.C., Kok A., Haagmans B.L., Tilanus H.W., and van der Laan L.J. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 131 (2006) 1452-1462
67. Firpi R.J., Nelson D.R., and Davis G.L. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 9 (2003) 57-61
68. Rostaing L., Izopet J., Sandres K., Cisterne J.M., Puel J., and Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 69 (2000) 991-994